Launch of anti-HIV drug Combivir generic a positive development for Lupin

MUMBAI: The launch of generic of anti-HIV drugCombivir is a positive development for Lupin. However, besides the innovator, it will have to share the market with two other competitors viz. Teva and Aurobindo Pharma.

The limited competition product has a market size of $ 275 million in the US. Lupin has a strong pipeline of such products to bank upon during the fiscal years 2013 and 2014.

While the company maintained strong growth in revenues at 24.5%, the bottomline plunged by 31% over the same quarter in the previous year.

The operating profit grew by 25.2% Exclusivity sales of product Ziprasidone and increased sales from its Japanese acquisition Irom were the major growth drivers for the net sales.

US, Japan and India are key markets for the company. All these have been growing at a strong rate. The company expects 25-30 launches in the US in the current fiscal.

In India, the company has a strong presence in the domestic formulations market and is outperforming the industry. In Japan too, the company is logging double-digit growth rate. The company's strategy and performance in these three geographies will hold the key to its future growth.